Formulary Monographs [MEDROXYPROGESTERONE, 6832]
|
|
MEDROXYPROGESTERONE
|
|
|
|
|
|
PROGESTINS
|
|
|
Anovulatory dysfunctional uterin e bleeding (DUB), post
menopausal hormone replacement therapy, contraception, carcinoma of the endometrium. |
|
|
Fluid retention, menstrual disorders. Use with caution in conditions which worsen fluid retention. c.f. prescribing in liver disease p. 15.
|
|
|
Oral: 2.5-10mg daily for at least 10 day s p er month as HRT; daily
from day s 16 or 21 of cycle for 5-10 days in anovulatory DUB. Higher p arenteral doses are required in endometrical cancer. |
|
|
|
|
|
|
|
|
|
|
|
|